A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Absorption of RO7795068 in Subjects with Obesity

The primary objective of this study is to evaluate the safety, absorption, and elimination of RO7795068, a novel compound investigated for the potential treatment of obesity. Determining these pharmacokinetic parameters is essential for establishing the metabolic profile and tolerability of the investigational product.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both male and female individuals. The participants belong to vulnerable populations with an age range corresponding to codes 3 and 4.

This Phase 3 clinical trial is designed to evaluate the safety, absorption, and elimination of RO7795068, a novel compound investigated for the potential treatment of obesity. The research methodology involves a structured sequence of study visits beginning with a screening visit to determine eligibility. Subsequent follow-up visits and an end-of-study visit are scheduled to monitor clinical outcomes and pharmacological parameters. The total duration of participant involvement is determined by the specific study protocols. Early termination from the study may occur based on predefined clinical criteria or safety requirements.

The provided documentation does not contain information regarding the specific parameters, methods, or instruments used to assess efficacy in this clinical trial.